benzoquinoxaline

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Benzoquinoxaline is a heterocyclic compound with a fused benzene and quinoxaline ring system. It is a versatile scaffold for the development of various pharmaceuticals and materials. Research on benzoquinoxaline focuses on its synthesis, pharmacological properties, and potential applications.

One prominent research area involves the synthesis of benzoquinoxaline derivatives. Various methods have been developed to synthesize benzoquinoxaline compounds, including condensation reactions between o-phenylenediamines and 1,2-dicarbonyl compounds.

Benzoquinoxaline derivatives have exhibited diverse pharmacological activities, such as anticancer, antimicrobial, anti-inflammatory, and antioxidant properties. For example, certain benzoquinoxaline derivatives have shown promising activity against various cancer cell lines.

The importance of benzoquinoxaline lies in its potential to serve as a building block for the development of new therapeutic agents. Its structural versatility allows for the introduction of different functional groups, leading to a wide range of potential pharmacological activities.

The study of benzoquinoxaline is driven by its potential to address various health challenges. Researchers continue to investigate its properties and explore its applications in medicine and other fields.'

Cross-References

ID Source	ID
PubMed CID	98494
SCHEMBL ID	730579
MeSH ID	M0102427

Synonyms (18)

Synonym
nsc48954
nsc-48954
230-33-1
benzo[f]quinoxaline
inchi=1/c12h8n2/c1-2-4-10-9(3-1)5-6-11-12(10)14-8-7-13-11/h1-8
benzoquinoxaline
benzo(f)quinoxaline
nsc 48954
5,6-benzoquinoxaline
unii-v7ujg79bn9
v7ujg79bn9 ,
SCHEMBL730579
1,4-diazaphenanthrene
YUFRAQHYKKPYLH-UHFFFAOYSA-N
DTXSID90177553
7,8-benzoquinoxaline
1,4-phenanthroline
benzochinoxalin

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	1 (20.00)	18.7374
1990's	1 (20.00)	18.2507
2000's	1 (20.00)	29.6817
2010's	1 (20.00)	24.3611
2020's	1 (20.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 54.73

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	54.73 (24.57)
Research Supply Index	1.79 (2.92)
Research Growth Index	4.80 (4.65)
Search Engine Demand Index	83.44 (26.88)
Search Engine Supply Index	2.00 (0.95)

This Compound (54.73)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	1 (20.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	4 (80.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
aminolevulinic acid Aminolevulinic Acid: A compound produced from succinyl-CoA and GLYCINE as an intermediate in heme synthesis. It is used as a PHOTOCHEMOTHERAPY for actinic KERATOSIS.. 5-aminolevulinic acid : The simplest delta-amino acid in which the hydrogens at the gamma position are replaced by an oxo group. It is metabolised to protoporphyrin IX, a photoactive compound which accumulates in the skin. Used (in the form of the hydrochloride salt)in combination with blue light illumination for the treatment of minimally to moderately thick actinic keratosis of the face or scalp.	1.96	1	4-oxo monocarboxylic acid; amino acid zwitterion; delta-amino acid	antineoplastic agent; dermatologic drug; Escherichia coli metabolite; human metabolite; mouse metabolite; photosensitizing agent; plant metabolite; prodrug; Saccharomyces cerevisiae metabolite
pyruvic acid Pyruvic Acid: An intermediate compound in the metabolism of carbohydrates, proteins, and fats. In thiamine deficiency, its oxidation is retarded and it accumulates in the tissues, especially in nervous structures. (From Stedman, 26th ed). pyruvic acid : A 2-oxo monocarboxylic acid that is the 2-keto derivative of propionic acid. It is a metabolite obtained during glycolysis.	1.96	1	2-oxo monocarboxylic acid	cofactor; fundamental metabolite
quinoxalines quinoxaline : A naphthyridine in which the nitrogens are at positions 1 and 4.	9.21	5	mancude organic heterobicyclic parent; naphthyridine; ortho-fused heteroarene
2-naphthylamine 2-Naphthylamine: A naphthalene derivative with carcinogenic action.. 2-naphthylamine : A naphthylamine carrying the amino group at position 2.	1.96	1	naphthylamine	carcinogenic agent
2,3-diaminonaphthalene [no description available]	1.96	1
valerates Valerates: Derivatives of valeric acid, including its salts and esters.	1.96	1	short-chain fatty acid anion; straight-chain saturated fatty acid anion	plant metabolite
4,5-dioxovaleric acid 4,5-dioxopentanoic acid : A dioxo monocarboxylic acid consisting of a valeric acid core with the two oxo groups at the 4- and 5-positions.	1.96	1	dioxo monocarboxylic acid
arabinose [no description available]	3.17	1	L-arabinose	Escherichia coli metabolite; mouse metabolite

Condition	Relationship Strength	Studies
ER-Negative PR-Negative HER2-Negative Breast Cancer [description not available]	2.31	1
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.31	1
Triple Negative Breast Neoplasms Breast neoplasms that do not express ESTROGEN RECEPTORS; PROGESTERONE RECEPTORS; and do not overexpress the NEU RECEPTOR/HER-2 PROTO-ONCOGENE PROTEIN.	2.31	1
Friedreich Disease [description not available]	2.05	1
Friedreich Ataxia An autosomal recessive disease, usually of childhood onset, characterized pathologically by degeneration of the spinocerebellar tracts, posterior columns, and to a lesser extent the corticospinal tracts. Clinical manifestations include GAIT ATAXIA, pes cavus, speech impairment, lateral curvature of spine, rhythmic head tremor, kyphoscoliosis, congestive heart failure (secondary to a cardiomyopathy), and lower extremity weakness. Most forms of this condition are associated with a mutation in a gene on chromosome 9, at band q13, which codes for the mitochondrial protein frataxin. (From Adams et al., Principles of Neurology, 6th ed, p1081; N Engl J Med 1996 Oct 17;335(16):1169-75) The severity of Friedreich ataxia associated with expansion of GAA repeats in the first intron of the frataxin gene correlates with the number of trinucleotide repeats. (From Durr et al, N Engl J Med 1996 Oct 17;335(16):1169-75)	2.05	1

chemdatabank.com